Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

10,250.00ILa
6:41am EDT
Change (% chg)

-90.00 (-0.87%)
Prev Close
10,340.00
Open
10,350.00
Day's High
10,390.00
Day's Low
10,220.00
Volume
326,207
Avg. Vol
612,333
52-wk High
21,770.00
52-wk Low
10,220.00

Latest Key Developments (Source: Significant Developments)

Teva to close or sell one of its Hungarian plants by end of 2018
Tuesday, 16 May 2017 10:23am EDT 

May 16 (Reuters) - Teva Pharmaceutical :* Teva plans to lay off 500 workers at Hungarian plant in Godollo in coming months - national news agency MTI reports, citing company..* Teva plans to close down or sell Godollo plant by end of 2018..* Plant in Godollo to operate with reduced capacity until mid-2018..* Teva says its plans do not affect its other two Hungarian plants in Debrecen and Sajobabony..  Full Article

Teva announces launch of generic Glumetza in the U.S.
Monday, 15 May 2017 01:20pm EDT 

May 15 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces launch of generic Glumetza® in the United States.Teva pharmaceutical says launch of generic Glumetza (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg, in U.S..  Full Article

Otsuka, Teva sign licensing agreement for Japan on TEV-48125
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Otsuka Pharmaceutical Co:Otsuka and Teva sign licensing agreement for Japan on prophylactic migraine drug candidate fremanezumab (TEV-48125).Teva Pharmaceutical Industries Ltd - with the agreement consummated, Otsuka is to pay Teva a lump-sum payment of $50 million.Teva Pharmaceutical Industries Ltd - future clinical trials in Japan will be carried out and funded by Otsuka.Teva Pharmaceutical Industries Ltd- in addition, Otsuka holds exclusive sales rights and will pay royalties on revenues to Teva.Teva Pharmaceutical-through agreement, otsuka secures exclusive rights in japan to fremanezumab, which teva is globally developing in other countries.  Full Article

Appaloosa LP takes share stake in BofA, UnitedHealth
Friday, 12 May 2017 04:44pm EDT 

May 12 (Reuters) - APPALOOSA LP:Appaloosa LP ups share stake in United Continental Holdings Inc to 364,615 shares from 160,000 shares.Appaloosa LP takes share stake of 300,000 shares in Unitedhealth Group Inc.Appaloosa LP takes share stake of 8.8 million shares in Bank Of America Corp - SEC filing.Appaloosa LP - Change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Teva qtrly non-GAAP EPS $1.06
Thursday, 11 May 2017 07:00am EDT 

May 11 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva reports first quarter 2017 financial results.Teva pharmaceutical industries ltd - qtrly gaap eps $0.57.Q1 revenue rose 17 percent to $5.6 billion.Teva pharmaceutical industries ltd - qtrly non-gaap eps $1.06.Teva pharmaceutical industries ltd - generic medicines revenues in q1 of 2017 were $3.1 billion, an increase of 24% compared to q1 of 2016.Teva pharmaceutical industries ltd - reaffirming full-year outlook.Teva pharmaceutical industries ltd - global revenues of copaxone were $970 million in q1 of 2017, a decrease of 4% compared to q1 of 2016.Teva pharmaceutical - have several challenges including u.s generics market dynamics and greater "instability" in venezuela market.Teva pharmaceutical industries ltd- specialty medicines revenues in q1 of 2017 were $2.0 billion, down 6% compared to q1 of 2016.Teva pharmaceutical industries ltd- now expect to realize cumulative net synergies and cost reduction of approximately $1.5 billion by end of 2017.Teva pharmaceutical industries ltd- michael mcclellan will serve as interim cfo, effective july 1, 2017.Teva pharmaceutical-pursuing sale of certain non-core assets, including global women's health business, oncology, pain business in europe, to pay down debt.  Full Article

Teva interim CEO sees more headcount reductions
Thursday, 11 May 2017 06:25am EDT 

May 11 (Reuters) - Teva Pharmaceutical Industries Ltd , TEVA.N:Interim CEO: headcount reduced by 5,000 since Actavis deal, expects more cuts by end of 2017.Interim CEO: deteriorating situation in Venezuela could impact ability to produce products there.  Full Article

Teva Pharmaceutical Industries expects that sales of authorized generic will represent most of sales of two products
Thursday, 20 Apr 2017 08:42am EDT 

April 20 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva launches airduo™ respiclick® and its authorized generic, two inhalers containing fluticasone propionate and salmeterol.Teva Pharmaceutical Industries Ltd- Expects that sales of authorized generic will represent most of sales of two products.  Full Article

Teva Pharmaceuticals received a warning letter from the U.S. FDA
Thursday, 13 Apr 2017 08:34am EDT 

Teva Pharmaceutical Industries Ltd :Teva Pharmaceutical Industries Ltd - on April 10, received a warning letter from the U.S. Food and Drug Administration (FDA) - SEC filing.  Full Article

Teva announces FDA approval of AUSTEDO tablets for treatment of chorea associated with huntington’s disease
Monday, 3 Apr 2017 05:04pm EDT 

Teva Pharmaceutical Industries Ltd - : Teva announces FDA approval of AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with huntington’s disease .AUSTEDO is expected to be available in U.S. within next 3 weeks..  Full Article

OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico
Monday, 20 Mar 2017 10:07am EDT 

OncBioMune Pharmaceuticals Inc : OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico . Term sheet sets forth guidelines for co to acquire sanitary registration, intellectual property rights of Norepinefrine .Norepinefrine is currently owned by Teva.  Full Article

More From Around the Web

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.